- 作者：J. de la Revilla Negro ; J.L. Martí ; nez Porras ; K. Torres Cruz ; J.L. Calleja Panero
- 关键词：Hepatitis C ; PCR ; VHC ; Cirrosis ; Interferó ; n pegilado ; Ribavirina ; Telaprevir ; Boceprevir
- 刊名：Medicine - Programa de Formaci贸n M茅dica Continuada Acreditado
- 出版年：2012
- 期刊代码：pca256_03045412
- 类别：med
- 出版时间：May, 2012
- 卷：11
- 期：9
- 页码：529-540
- 文件大小：378 K
HCV infection is recognized as a global world health problem. HCV can evade innate immune responses, thereby increasing the risk of chronicity. Acute HCV infection use to be asymptomatic. The majority of cases develop a chronic infection. Chronic HCV is associated with variable degrees of inflammation and fibrosis. Liver disease could progress to cirrhosis and develops clinical complications. Diagnosis is based on the presence of both anti-HCV antibodies and HCV replication. The combination of pegylated interferon and ribavirin has been the accepted standard of care. The main indication for treatment is the degree of liver damage. However, with the standard combination therapy only half of all the patients can be cured and it is associated with a numerous side effects. Currently there are two new compounds available that should be used in addition to peg-interferon and ribavirin. This new triple therapy increases antiviral efficacy with a response-guided schedule.